Edwards Lifesciences consensus stays cautious, shares priced below analyst targets
26.06.2026 - 12:42:27 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 12:41.
Edwards Lifesciences (US28176E1082) opens Friday’s NASDAQ session with a stable analyst picture and a share price below most published targets. The latest data from several research aggregators put the consensus 12-month price objective in the mid-90 dollar range for the EW shares, while the stock most recently traded just under 90 dollars according to a market snapshot.
What analysts are currently pricing in
Across major Wall Street houses, Edwards Lifesciences is predominantly rated in the Buy and Hold spectrum, with only a small minority on Sell, as collated by consensus platforms that track broker recommendations for the EW ticker. The average target price sits a few dollars above the current market level, implying that analysts still model mid-single-digit to low double-digit upside over the next 12 months. Many models hinge on continued growth in transcatheter aortic valve replacement (TAVR) procedures and disciplined operating margins, themes that recur in recent research notes from large firms such as Goldman Sachs and JPMorgan that follow the broader S&P 500 medtech space.
Valuation discussions frequently compare Edwards Lifesciences to larger cardiovascular peers like Medtronic and Abbott Laboratories, where multiples on forward earnings have compressed over the past year as investors reassessed growth expectations for elective procedures. Against this backdrop, Edwards’ premium multiple remains tied to expectations for above-sector revenue growth and a high-return product pipeline in structural heart therapies, according to market commentary on U.S. medical device stocks.
Focus on earnings and profitability metrics
The consensus also reflects relatively tight expectations for upcoming quarterly numbers, with analysts projecting mid-single-digit to low double-digit revenue growth and stable to slightly expanding operating margins for 2026, based on compiled estimates from earnings-calendars that track Edwards Lifesciences. Free cash flow generation and capital allocation - including R&D spending levels and selective bolt-on acquisitions - are central discussion points in recent broker models for the company. Several houses underline that upside to estimates would likely require faster adoption of newer structural heart indications or a stronger-than-expected recovery in procedure volumes in key regions.
Edwards Lifesciences reports under the S&P 500 healthcare umbrella, which means its results are often benchmarked against the broader medtech cohort on NASDAQ and NYSE when major U.S. indices move around macro events such as Federal Reserve meetings. In these comparisons, analysts highlight the company’s relatively low net debt position and robust profitability as supportive factors for the valuation, even as some research notes caution about competition in TAVR and pricing dynamics in mature markets.
All news and analysis on the Edwards Lifesciences shares
Price data, ad-hoc announcements and further analyst commentary on Edwards Lifesciences are bundled in the dedicated topic section for the EW listing.
How Edwards Lifesciences makes its money
Edwards Lifesciences generates most of its revenue from transcatheter heart valve therapies, in particular its Sapien family of TAVR valves and related delivery systems used to treat aortic stenosis. Additional income comes from surgical structural heart products such as repair and replacement valves, as well as critical care monitoring technologies used in intensive care and operating rooms worldwide. The company invests a high single-digit percentage of sales in research and development to expand indications and develop next-generation devices in structural heart disease.
Where the shares trade today
The Edwards Lifesciences shares (US28176E1082) last traded on NASDAQ at around 89 to 90 US dollars on 2026-06-25, 22:00, placing the company’s equity value in the large-cap segment of the S&P 500 medtech cohort.
Key data on the Edwards Lifesciences shares
- Company: Edwards Lifesciences Corporation
- ISIN: US28176E1082
- WKN: 936853
- Ticker: EW
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 22:00): 89.72 USD
- Market cap: 54.0 billion USD (as of 2026-06-25)
- Sector / industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-07-24
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.
